Literature DB >> 16490587

Different methods of presenting risk information and their influence on medication compliance intentions: results of three studies.

Sean D Young1, Daniel M Oppenheimer.   

Abstract

BACKGROUND: Pharmaceutical noncompliance is an increasingly important problem in the United States, leading to hundreds of thousands of deaths and billions of wasted dollars each year. Patients' fear of adverse events (AEs) is one possible reason for lack of compliance.
OBJECTIVES: The aims of the 3 studies described in this article were to investigate whether commonly used methods of conveying AE risk might influence subjects' perceptions of their risk of experiencing drug-related AEs and whether disclosing this information by other means might subsequently influence their intentions to comply with prescribed medication regimens.
METHODS: In study 1, randomly selected participants were surveyed to estimate their percentage risk for medication AEs. In study 2, randomly selected participants were presented with a fictitious medical scenario, informed of their AE risk either in terms of specific percentages or in general semantic terms (eg, "some people may experience"), and then asked to rate their fear of AEs and likelihood of compliance. Study 3 was a randomized, controlled experiment in which we duplicated the methods of study 2, with the addition of real-life stimuli (pharmaceutical advertisements).
RESULTS: In study 1, 40 subjects were surveyed. Participants overestimated their risk of AEs when information was disclosed semantically. In study 2, people were more fearful of experiencing AEs and less likely to intend to comply with prescribed medication regimens (both, P < 0.01) when presented with AE risk information in the form of semantic risk frames rather than actual risk percentages. In study 3, 120 subjects participated. Again, participants expressed stronger intent to comply with medication regimens when they received AE risk information as percentages rather than in semantic terms (P < 0.04). In addition, intended likelihood to comply was negatively correlated with fear of experiencing AEs (P < 0.01).
CONCLUSIONS: In these studies, informing participants of actual percentage risk of AEs was associated with less fear about AEs and greater intent to comply with prescribed regimens. Using verbal descriptors to disclose AE risk information was associated with less intent to comply.

Entities:  

Mesh:

Year:  2006        PMID: 16490587     DOI: 10.1016/j.clinthera.2006.01.013

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  8 in total

Review 1.  Aripiprazole in acute mania and long-term treatment of bipolar disorder: a critical review by an Italian working group.

Authors:  Pasquale De Fazio; Paolo Girardi; Giuseppe Maina; Massimo Carlo Mauri; Mauro Mauri; Palmiero Monteleone; Giulia Ida Perini; Giulio Perugi; Alessandro Rossi
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  Effect of communication strategy on personal risk perception and treatment adherence intentions.

Authors:  Sean Young; Daniel M Oppenheimer
Journal:  Psychol Health Med       Date:  2009-08       Impact factor: 2.423

Review 3.  Written information about individual medicines for consumers.

Authors:  Donald Nicolson; Peter Knapp; D K Theo Raynor; Pat Spoor
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15

4.  Understanding rational non-adherence to medications. A discrete choice experiment in a community sample in Australia.

Authors:  Tracey-Lea Laba; Jo-Anne Brien; Stephen Jan
Journal:  BMC Fam Pract       Date:  2012-06-20       Impact factor: 2.497

5.  Exploring consumer opinions on the presentation of side-effects information in Australian Consumer Medicine Information leaflets.

Authors:  Vivien Tong; David K Raynor; Susan J Blalock; Parisa Aslani
Journal:  Health Expect       Date:  2014-06-06       Impact factor: 3.377

6.  Does price disclosure in pharmaceutical advertising result in price transparency? Evidence from a randomized experiment.

Authors:  Ilene L Hollin; Jennifer Gerard Ball
Journal:  Explor Res Clin Soc Pharm       Date:  2022-09-19

7.  Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports.

Authors:  R Andrew Moore; Sheena Derry; Henry J McQuay
Journal:  Arthritis Res Ther       Date:  2008-05-08       Impact factor: 5.156

8.  Imprecision and Preferences in Interpretation of Verbal Probabilities in Health: a Systematic Review.

Authors:  Katerina Andreadis; Ethan Chan; Minha Park; Natalie C Benda; Mohit M Sharma; Michelle Demetres; Diana Delgado; Elizabeth Sigworth; Qingxia Chen; Andrew Liu; Lisa Grossman Liu; Marianne Sharko; Brian J Zikmund-Fisher; Jessica S Ancker
Journal:  J Gen Intern Med       Date:  2021-08-06       Impact factor: 5.128

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.